Patent ID: 11919918
Assignee: BEIJING TIDE PHARMACEUTICAL CO., LTD.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. A method for the treatment of a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist, wherein the method comprises administering to a subject in need thereof an effective amount of a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, polymorph, solvate, N-oxide, isotopically labeled compound or prodrug thereof:, wherein:
L is O;
V1 is selected from the group consisting of N,, , and NR;
 represents either a single bond or a double bond, provided that when  is a single bond, V1 is NR and V2 is C(═O);
R is selected from the group consisting of H, halogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, saturated or partially unsaturated C3-10 cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C6-10 aryl, 5- to 14-membered heteroaryl and C6-12 aralkyl, and at most 2 ring members in the cyclic hydrocarbyl and heterocyclyl are C(═O);
R1, R2, R3 and R6 are each independently selected from the group consisting of H, halogen, —CN, —NH2, —OH, —SH, —Se—R, —Si(R)3, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, saturated or partially unsaturated C3-10 cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C6-10 aryl, 5- to 14-membered heteroaryl, C6-12 aralkyl, C1-6 haloalkyl, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —ORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRb, —S(═O)(═NR)Ra, —NRaRb, —C(═O)NRaRb, —C(═S)NRaRb, —C(═NR)NRaRb, —NRa—C(═O)Rb, —NRa—C(═O)ORb, —NRa—S(═O)2—Rb, —NRa—C(═O)—NRaRb, —C1-6 alkylene-NRaRb, —C1-6 alkylene-ORa, —C1-6 alkylene- C(═O)R, —C1-6 alkenylene-ORa, —O—C1-6 alkylene-NRaRb and —P(═O)RaRb;
R4 and R5 are each independently selected from the group consisting of H, —C(═O)ORa, —NRaRb, —NRa—C(═O)Rb, —NRa—C(═O)ORb, —C1-6 alkylene-NRaRb, —C1-6 alkylene-ORa, —C1-6 alkylene-O—C1-6 alkylene-ORa, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, saturated or partially unsaturated C3-10 cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C6-10 aryl, 5- to 14-membered heteroaryl and C6-12 aralkyl;
alternatively, R1 and R4 together form —NH—(C1-6 alkylene)-L-(C1-6 alkylene)-;
the above alkyl, alkylene, alkenyl, alkynyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl, at each occurrence, are each optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, —Si(R)3, C1-6 alkyl, saturated or partially unsaturated C3-6 cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C6-10 aryl, 5- to 14-membered heteroaryl, C6-12 aralkyl, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORa, —ORa, —SRa, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRaRb, —NRaRb, —C(═O)NRaRb, —NRa—C(═O)Rb, —NRa—C(═O)ORb, —NRa—S(═O)2—Rb, —NRa—C(═O)—NRaRb, —C1-6 alkylene-NRaRb, —C1-6 alkylene-ORa, —C1-6 alkenylene-ORa and —O—C1-6 alkylene-NRaRb, the alkyl, cyclic hydrocarbyl, heterocyclyl, aryl, heteroaryl and aralkyl are further optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, oxo, amino, cyano, nitro, —NRaRb, C1-6 alkyl, —O—C1-6 alkyl, saturated or partially unsaturated C3-6 cyclic hydrocarbyl, saturated or partially unsaturated 3- to 10-membered heterocyclyl, C6-10 aryl, 5- to 14-membered heteroaryl and C6-12 aralkyl; and
Ra and Rb, at each occurrence, are each independently selected from the group consisting of H, —OH, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, phenyl, benzyl, methoxy and ethoxy; or, R1 and Rb together with the atom to which they are attached form a 5- to 8-membered heterocycle or heteroaromatic ring.